Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis

• Status: Terminated
• Trial end date: 2018-04-18
• Target enrollment: 0
• Participant gender: All

Summary

The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales. The severity of the disease varies, but in many cases it can have a major impact on their quality of life if not adequately treated.

The purpose of the study is to determine the short term safety, pharmacodynamic and clinical effect of AZD0284 in patients with psoriasis.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Provision of signed informed consent prior to any study specific procedures.

• At least 6 months documented history with a diagnosis of moderate to severe plaque psoriasis as defined by the Psoriasis Area and Severity Index (PASI), psoriasis Body Surface Area (BSA) and static Physician Global Assessment (sPGA).

Exclusion Criteria:

• History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study.

• History and/or presence of tuberculosis, hepatitis, HIV. Other opportunistic infections within 6 months of the study.

• Clinically significant laboratory abnormalities.

• Clinically important abnormalities in rhythm, conduction or morphology of the digital Electrocardiogram (ECG) as considered by the Investigator may interfere with the interpretation of study data.

• Current treatment or treatment for psoriasis with biological therapies within 6 months of study.

• Efficacy and safety failure of biologic therapies targeting the IL-17 and IL12/23 pathway at any time.

• Current treatment or history of treatment for psoriasis with non-biological systemic medications within 4 weeks of Day 1